BiotechTube

Liposomal amphotericin B (AmBisome®) + Liposomal amphotericin B (AmBisome®)

ApprovedTerminated
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Febrile Neutropenia

Conditions

Febrile Neutropenia

Trial Timeline

Mar 1, 2007 → May 1, 2008

NCT ID
NCT00421187

About Liposomal amphotericin B (AmBisome®) + Liposomal amphotericin B (AmBisome®)

Liposomal amphotericin B (AmBisome®) + Liposomal amphotericin B (AmBisome®) is a approved stage product being developed by Gilead Sciences for Febrile Neutropenia. The current trial status is terminated. This product is registered under clinical trial identifier NCT00421187. Target conditions include Febrile Neutropenia.

What happened to similar drugs?

3 of 7 similar drugs in Febrile Neutropenia were approved

Approved (3) Terminated (3) Active (2)
✅Imipenem + ImipenemMerckApproved
✅Ceftolozane-Tazobactam + MeropenemMerckApproved
✅Ceftolozane-tazobactam IVMerckApproved
❌HHPG-19K InjectionJiangsu Hengrui MedicinePhase 3
❌Daptomycin + DaptomycinMerckPhase 3
🔄linezolid + vancomycinPfizerPhase 3
🔄ciprofloxacin + cefepimeBayerPhase 3

Hype Score Breakdown

Clinical
20
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00421187ApprovedTerminated

Competing Products

8 competing products in Febrile Neutropenia

See all competitors
ProductCompanyStageHype Score
HHPG-19K InjectionJiangsu Hengrui MedicinePhase 3
32
Imipenem + ImipenemMerckApproved
43
Ceftolozane-Tazobactam + MeropenemMerckApproved
50
Ceftolozane-tazobactam IVMerckApproved
35
Daptomycin + DaptomycinMerckPhase 3
32
linezolid + vancomycinPfizerPhase 3
40
Antibacterial agent for the treatment of febrile neutropeniaPfizerPre-clinical
26
ciprofloxacin + cefepimeBayerPhase 3
37